Experience With the Use of Baricitinib and Tocilizumab Monotherapy or Combined, in Patients With Interstitial Pneumonia Secondary to Coronavirus COVID19: A Real-World Study

Mostrar otras versiones (1)

OBJECTIVE: To describe the experience of treatment with baricitinib (BARI) and/or tocilizumab (TCZ), in monotherapy or combined, in patients admitted for interstitial pneumonia secondary to COVID19, and for 30 days after discharge. METHODS: Medical records of patients admitted with COVID19 and IP wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosas, José, Liaño, Francisco Pasquau, Cantó, Mónica Llombart, Barea, José María Carrasco, Beser, Amparo Raga, Rabasa, José Tomás Algado, Adsuar, Francisco Martínez, Auli, Brian Vila, López, Isabel Fernández, Sainz, Ana María Garijo, Ramis, Pere Esquerdo, Pérez, Laura Ruiz, Rebollo, Mª Luisa Navarrete, Lorido, Raquel Hernández, Escolar, Laura Gómez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699160/
https://www.ncbi.nlm.nih.gov/pubmed/33358361
http://dx.doi.org/10.1016/j.reuma.2020.10.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699160/
https://www.ncbi.nlm.nih.gov/pubmed/33358361
http://dx.doi.org/10.1016/j.reuma.2020.10.009

Ejemplares similares